Clinical Trials Begin for Stem Cell-Based Cancer Immunotherapy

Cancer immunotherapy has brought revolutionary advances to cancer treatment in recent years. In particular, the use of natural killer cells (NK) together with immune checkpoint inhibitors is described as an effective strategy for cancer treatment. In this context, natural killer cancer cells derived from induced pluripotent stem cells have begun to be tested in cancer patients for the first time in clinical trials. These cells have the property of being ready to use off the shelf . This makes them suitable for use in every patient.
In 2006, researchers developed induced pluripotent stem cells by activating 4 genes that were inactive in skin cells. Induced pluripotent stem cells have characteristics of embryonic stem cells and can become any cell type. Most cellular immunotherapies currently used involve the patient’s own cells or cells obtained from a donor. While this approach forms the basis of personalized treatment, it is very expensive and time-consuming. By contrast, using induced pluripotent stem cells allows the production of cells in the desired numbers and with the desired characteristics. A single induced pluripotent stem cell enables the use of “off-the-shelf” cells for treatment. This saves time.
In 2013, Dr. Dan Kaufman and his team at the San Diego School of Medicine developed a method for producing natural killer cells against cancer from human induced pluripotent stem cells. Following advanced preclinical research, the United States Food and Drug Administration (FDA) granted accelerated clinical trial approval last November to test induced pluripotent stem cell-dependent natural killer cell immunotherapy in patients with advanced solid tumors.
The phase-I clinical trial was launched with 64 patients with advanced, incurable cancers in February 2019. Its purpose is to test the safety of this treatment. Other objectives are to determine how tumors respond to natural killer cell treatments and how long they remain in patients’ bodies.
In the clinical trial, natural killer cells will be administered once a week for 3 weeks. This treatment is used together with one of 3 immune checkpoint inhibitors (nivolumab, pembrolizumab, and atelizumab).
What Does This Advance Mean for Us?
- This clinical trial is a first for stem cell-based cancer immunotherapy. It involves using human-derived induced pluripotent stem cells against cancer.
- Natural killer cancer cells derived from induced pluripotent stem cells effectively destroyed cancer cells in cell culture and mouse models.
- The study results are expected to be announced in 2022.
- It is important to emphasize that modern medicine continues to seek solutions against cancer through all branches of science. In the very near future, we will see gene therapies, CAR T-cell therapies, and stem cell therapies.
Sources
ir.fatetherapeutics.com 30 Nov 2018.
2. Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, Lee DA, Kaufman DS.
Clinical‐Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy.
Stem Cells Transl Med. April 2013.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.